EYPT News and Press, EyePoint Pharmaceuticals Inc. From 03/12/24

2024-03-12 08:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-08 15:30:02 ET H.C. Wainwright analyst issues BUY recommendation for EYPT on March 8, 2024 03:00PM ET. The previous analyst recommendation was Buy. EYPT was trading at $24.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-03-07 12:29:03 ET EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call March 07, 2024, 08:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call P...

2024-03-07 07:04:05 ET More on EyePoint Pharmaceuticals EyePoint Is Betting The Bank On EYP-1901 EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time JP Morgan starts EyePoint at overweight, cites eye drug potential Seeking Alpha ...

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clin...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-06 10:28:05 ET More on EyePoint Pharmaceuticals EyePoint Is Betting The Bank On EYP-1901 EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time JP Morgan starts EyePoint at overweight, cites eye drug potential Seeking Alpha ...

– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR – – Initiation of first Phase 3 clinical trial (LUGANO) of EYP-1901 in wet AMD expected in 2H 2024 – WATERTOWN, M...

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webca...

2024-02-21 08:36:08 ET Summary EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. E...